Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Assembly Biosciences's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -264.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Assembly Biosciences's 1-Year ROIIC % or its related term are showing as below:
FRA:V7B's 1-Year ROIIC % is ranked worse than 80.52% of 1340
companies
in the Biotechnology industry
Industry Median: -9.345
vs FRA:V7B: -264.13
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Assembly Biosciences 1-Year ROIIC % Related Terms
Assembly Biosciences 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:V7B vs CTNM, PRTA, RGNX: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Assembly Biosciences's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's 1-Year ROIIC % falls into.
Assembly Biosciences's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -11.817 (Mar. 2026) - -41.3356 (Mar. 2025) )
/
( 30.21 (Mar. 2026) - 43.164 (Mar. 2025) )
=
29.5186
/
-12.954
=
-227.87%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Assembly Biosciences (FRA:V7B) has a 1-Year ROIIC % of -264.13 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #1079 out of 1340 companies in the Biotechnology industry, placing it in the top 80.5%.
Is Assembly Biosciences' 1-Year ROIIC % too high?
Assembly Biosciences' current 1-Year ROIIC % is -264.13. Based on the distribution chart, Assembly Biosciences ranks #1079 out of 1340 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Assembly Biosciences has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' 1-Year ROIIC % compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #1079 out of 1340 companies for 1-Year ROIIC %. This places Assembly Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current 1-Year ROIIC % is -264.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Assembly Biosciences (FRA:V7B) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.56, compared to a current price of €21.85 — trading 24.4% above its estimated fair value. The current 1-Year ROIIC % is -264.13. Assembly Biosciences' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Assembly Biosciences (FRA:V7B), the current 1-Year ROIIC % is -264.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Assembly Biosciences (FRA:V7B) Overvalued in 2026?
Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued.
The current stock price of €21.85 is trading 24.4% above its estimated GF Value™ of €17.56.
GuruFocus considers Assembly Biosciences to be Modestly Overvalued.
Key valuation signals for FRA:V7B:
1-Year ROIIC %: -264.13
GF Value™: €17.56 vs. price of €21.85 (24.4% above fair value)
No single metric tells the full story. See the FRA:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
37GF Score
Get the complete analysis for FRA:V7B
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V7B has been successfully added to your 
